Document is current
Any future updates will be listed below
-
Authors
Hansen, Björn M. https://orcid.org/0000-0001-8661-9063
Hall, Emma https://orcid.org/0009-0002-0026-974X
Szolics, Alex https://orcid.org/0009-0006-5050-7696
Andersson, Tommy https://orcid.org/0000-0001-8202-7829
Wassélius, Johan https://orcid.org/0000-0003-1896-381X
-
Funding
Funding for this research was provided by:
Teggerstiftelsen
Regional ALF grants
Crafoordska Stiftelsen
VINNOVA
SUS Stiftelser & Fonder
SUS Stiftelser & Fonder
Lund University
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 15 September 2025
First Online: 22 September 2025
Declarations
:
: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J. Wassélius is a founder and shareholder of Uman Sense AB and has received speaker honoraria from Siemens Healthineers, Balt group and Medtronic Inc. T. Andersson is a consultant for Anaconda, Johnson & Johnson/Neuravi, Ceretrieve, Cortirio, Optimize Neurovascular, Rapid Medical and SPRYTE, and a founder and shareholder of Ceroflo. B.M. Hansen, E. Hall and A. Szolics declare that they have no competing interests.
: The Swedish Ethical Review Authority approved the study and waived individual informed consent (#2019/00678 and #2022-00890-02).
